Clinical growth Protara Therapeutics is advancing TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, presenting a clear expansion opportunity for partnerships or services around translational research, clinical development support, and regulatory consulting as trials advance.

IV Choline Chloride The development of IV Choline Chloride for parenteral nutrition-reliant patients signals a potential niche for manufacturing, supply chain optimization, and clinical support services focused on rare disease indications and specialized pharmaceutical logistics.

Funding runway With substantial funding and a mid-sized employee base, Protara may be open to strategic collaborations, manufacturing scale-up agreements, or co-development deals to accelerate late-stage trials and commercialization readiness.

Industry visibility Active participation in major oncology and urology conferences indicates openness to partnerships, investigator-initiated studies, and sponsored research opportunities that could complement BD efforts and expand their network in oncology and nephrology spaces.

Tech-enabled ops Existing tech stack (NetSuite, Smartsheet, Box, Greenhouse) suggests readiness for vendor collaboration in enterprise solutions, supply chain optimization, data management, and outsourced R&D services to improve trial execution and reporting.